慢性阻塞性肺疾病药物研究进展

被引:3
作者
李伟
宁奇
张秀平
机构
[1] 上海医药工业研究院
[2] 上海医药工业研究院 上海
[3] 上海
[4] 上海
关键词
慢性阻塞性肺疾病; 支气管扩张剂; 糖皮质激素; 磷酸二酯酶4(PDE4); 炎症介质阻滞剂; 蛋白酶抑制剂; 黏液调整剂;
D O I
暂无
中图分类号
R563.9 [其他];
学科分类号
摘要
慢性阻塞性肺疾病(COPD)是一种常见病,在世界范围内发病率逐年上升。现对其防治药物,如支气管扩张剂、糖皮质激素、磷酸二酯酶4(PDE4)抑制剂、炎症介质阻滞剂、蛋白酶抑制剂、黏液调整剂等研究进展做一综述。
引用
收藏
页码:295 / 300
页数:6
相关论文
共 13 条
[1]  
The effects of a specific neutrophil elastase inhibitor (ONO-5046) in pulmonary ischemia–reperfusion injury[J] . Norihiko Ishikawa,Makoto Oda,Masahiko Kawaguchi,Yoshio Tsunezuka,Go Watanabe.Transplant International . 2003 (5)
[2]  
Neutrophil elastase and acute lung injury: Prospects for sivelestat and other neutrophil elastase inhibitors as therapeutics[J] . Bernhardt G. Zeiher,Shozo Matsuoka,Kazuhito Kawabata,John E. Repine.Critical Care Medicine . 2002 (5 Su)
[3]   Salmeterol plus theophylline combination therapy in the treatment of COPD [J].
ZuWallack, RL ;
Mahler, DA ;
Reilly, D ;
Church, N ;
Emmett, A ;
Rickard, K ;
Knobil, K .
CHEST, 2001, 119 (06) :1661-1670
[4]  
Phosphodiesterase 4 inhibitors, structurally unrelated to Rolipram, as promising agents for the treatment of asthma and other pathologies[J] . Vittorio Dal Piaz,Maria Paola Giovannoni.European Journal of Medicinal Chemistry . 2000 (5)
[5]  
Tiotropium (SPIRIVA ? ): Mechanistical considerations and clinical profile in obstructive lung disease[J] . Bernd Disse,Georg A. Speck,Karl Ludwig Rominger,Theodore J. Witek,Rudolf Hammer.Life Sciences . 1999 (6)
[6]  
Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?[J] . M.M. Teixeira,R.W. Gristwood,N. Cooper,P.G. Hellewell.Trends in Pharmacological Sciences . 1997 (5)
[7]  
Adverse Effects of Corticosteroid Therapy for COPD[J] . Charlene E McEvoy,Dennis E Niewoehner.Chest . 1997 (3)
[8]  
Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease[J] . Peter J Barnes,Maria G Belvisi,Judith C.W. Mak,El-Bdaoui Haddad,Brian O’Connor.Life Sciences . 1995 (11)
[9]  
long-actingβ2 agonists in the management of stablechronic obstructive pulmonary disease. Cazzola M, Donner CF. Drugs . 2000
[10]  
Cilomilast (Ariflo ) 15mg bid safety in a 6-month clinical trial program. Compton CH, Edelson JD, Cedar E, et al. American Journal of Respiratory and Critical Care Medicine . 2001